What did @dr.tommymartin actually say?
Dr. Martin pushed back against fitness influencer Jillian Michaels' framing of GLP-1 medications, arguing that obesity is a chronic medical condition, not a willpower failure. He walked through semaglutide trial data, covered common and serious side effects, and made the case that weight regain after stopping is a feature of the disease, not a character flaw. He also distinguished between Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight loss), which is a distinction many creators skip entirely.
His core argument: "Please do not let fitness influencers, even the ones as popular as Jillian Michaels, shame you for needing a medication for weight loss or weight maintenance." That is a defensible position. The question is whether the supporting evidence he cited was accurate.
Does the science back this up?
Mostly, yes. The 15% body weight loss figure he cites is consistent with published data, and the cardiovascular benefits claim has since been confirmed in a landmark trial. Where he gets loose is in how he frames the trial conditions.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed a 14.9% mean weight reduction in the semaglutide group versus 2.4% in the placebo group over 68 weeks. That is close to his "about 15%" and "around 2.5%" figures. The two-year extension data from STEP 5 (Garvey et al., 2022, Nature Medicine) does confirm sustained weight loss around 15% with continued use, so that check out too.
The cardiovascular benefits claim is supported by the SELECT trial (Lincoff et al., 2023, New England Journal of Medicine), which found a 20% reduction in major adverse cardiovascular events in people with obesity and established cardiovascular disease. The renal benefits claim has support from the FLOW trial (Perkovic et al., 2024, New England Journal of Medicine), which showed slowed kidney disease progression with semaglutide. He is not making those up.
What did they get wrong (or right)?
He got the drug naming slightly wrong and glossed over a meaningful limitation of the trial data. On the naming: he repeatedly called semaglutide "ozimpic lutide," which is not a real drug name. Semaglutide is the active ingredient in both Ozempic and Wegovy. That is a presentation error, not a science error, but sloppy terminology in medical content erodes trust.
More meaningfully, he says these trials require "intensive lifestyle modifications" alongside medication, which is accurate. But he does not tell viewers what that actually means. In STEP 1, participants received counseling on a 500 kcal/day deficit diet and 150 minutes of physical activity per week. That context matters a lot for anyone watching and thinking the drug alone produces 15% weight loss. Real-world outcomes without that support are more variable.
His claim that patients regain "about two thirds of the weight" after stopping is accurate, drawn from the STEP 1 withdrawal extension (Wilding et al., 2022, Diabetes, Obesity and Metabolism). Credit where it is due: he presented that honestly instead of burying it.
What should you actually know?
The science on GLP-1 receptor agonists is strong and getting stronger. This is not a fringe medication class or a quick fix dressed up in trial data. It is one of the more well-studied pharmacological interventions in obesity medicine in the last two decades. Dr. Martin's overall message is grounded in legitimate evidence.
That said, a few things this video does not cover matter clinically:
- Side effect rates in trials were meaningful. In STEP 1, 44% of semaglutide participants experienced nausea, and discontinuation due to side effects ran around 7%. "Most common side effects" language can minimize how disruptive GI symptoms are for real patients.
- Pancreatitis risk is listed as a warning, but the absolute risk remains low and the causality debate is ongoing. Calling it "rare but serious" is appropriate.
- Tirzepatide (Mounjaro, Zepbound) is a GIP/GLP-1 dual agonist with even larger weight loss data in the SURMOUNT trials, showing mean losses over 20% in some cohorts. Lumping all GLP-1 class drugs together misses meaningful differences between agents.
- Access and cost are not mentioned. For a medication that may need to be taken indefinitely, that is a significant omission for any patient-facing content.
Bottom line
Dr. Martin is doing more good than harm here. His core claims are anchored in real trials, he correctly distinguishes indications, and he presents weight regain data honestly. The anti-stigma framing is not just feel-good messaging, it is supported by research showing weight bias impairs health outcomes (Puhl and Heuer, 2009, Obesity). The imprecise drug naming and thin contextual framing of trial conditions are real weaknesses, but they do not undermine the overall accuracy of the content.